PMID- 30649675 OWN - NLM STAT- MEDLINE DCOM- 20190722 LR - 20190722 IS - 1573-7241 (Electronic) IS - 0920-3206 (Linking) VI - 33 IP - 1 DP - 2019 Feb TI - Comparative Analysis of Long-Term Outcomes of Torasemide and Furosemide in Heart Failure Patients in Heart Failure Registries of the European Society of Cardiology. PG - 77-86 LID - 10.1007/s10557-018-6843-5 [doi] AB - PURPOSE: Current clinical recommendations do not emphasise superiority of any of diuretics, but available reports are very encouraging and suggest beneficial effects of torasemide. This study aimed to compare the effect of torasemide and furosemide on long-term outcomes and New York Heart Association (NYHA) class change in patients with chronic heart failure (HF). METHODS: Of 2019 patients enrolled in Polish parts of the heart failure registries of the European Society of Cardiology (Pilot and Long-Term), 1440 patients treated with a loop diuretic were included in the analysis. The main analysis was performed on matched cohorts of HF patients treated with furosemide and torasemide using propensity score matching. RESULTS: Torasemide was associated with a similar primary endpoint (all-cause death; 9.8% vs. 14.1%; p = 0.13) occurrence and 23.8% risk reduction of the secondary endpoint (a composite of all-cause death or hospitalisation for worsening HF; 26.4% vs. 34.7%; p = 0.04). Treatment with both torasemide and furosemide was associated with the significantly most frequent occurrence of the primary (23.8%) and secondary (59.2%) endpoints. In the matched cohort after 12 months, NYHA class was higher in the furosemide group (p = 0.04), while furosemide use was associated with a higher risk (20.0% vs. 12.9%; p = 0.03) of worsening >/= 1 NYHA class. Torasemide use impacted positively upon the primary endpoint occurrence, especially in younger patients (aged < 65 years) and with dilated cardiomyopathy. CONCLUSIONS: Our findings contribute to the body of research on the optimal diuretic choice. Torasemide may have advantageous influence on NYHA class and long-term outcomes of HF patients, especially younger patients or those with dilated cardiomyopathy, but it needs further investigations in prospective randomised trials. FAU - Ozieranski, Krzysztof AU - Ozieranski K AD - Department of Cardiology, Public Central Teaching Hospital in Warsaw, Medical University of Warsaw, 1a Banacha St., 02-097, Warsaw, Poland. FAU - Balsam, Pawel AU - Balsam P AD - Department of Cardiology, Public Central Teaching Hospital in Warsaw, Medical University of Warsaw, 1a Banacha St., 02-097, Warsaw, Poland. pawel.balsam@wum.edu.pl. FAU - Kaplon-Cieslicka, Agnieszka AU - Kaplon-Cieslicka A AD - Department of Cardiology, Public Central Teaching Hospital in Warsaw, Medical University of Warsaw, 1a Banacha St., 02-097, Warsaw, Poland. FAU - Tyminska, Agata AU - Tyminska A AD - Department of Cardiology, Public Central Teaching Hospital in Warsaw, Medical University of Warsaw, 1a Banacha St., 02-097, Warsaw, Poland. FAU - Kowalik, Robert AU - Kowalik R AD - Department of Cardiology, Public Central Teaching Hospital in Warsaw, Medical University of Warsaw, 1a Banacha St., 02-097, Warsaw, Poland. FAU - Grabowski, Marcin AU - Grabowski M AD - Department of Cardiology, Public Central Teaching Hospital in Warsaw, Medical University of Warsaw, 1a Banacha St., 02-097, Warsaw, Poland. FAU - Peller, Michal AU - Peller M AD - Department of Cardiology, Public Central Teaching Hospital in Warsaw, Medical University of Warsaw, 1a Banacha St., 02-097, Warsaw, Poland. FAU - Wancerz, Anna AU - Wancerz A AD - Department of Cardiology, Public Central Teaching Hospital in Warsaw, Medical University of Warsaw, 1a Banacha St., 02-097, Warsaw, Poland. FAU - Marchel, Michal AU - Marchel M AD - Department of Cardiology, Public Central Teaching Hospital in Warsaw, Medical University of Warsaw, 1a Banacha St., 02-097, Warsaw, Poland. FAU - Crespo-Leiro, Maria G AU - Crespo-Leiro MG AD - Unidad de Insuficiencia Cardiaca Avanzada y Trasplante Cardiaco, Hospital Universitario A Coruna, CIBERCV, La Coruna, Spain. FAU - Maggioni, Aldo P AU - Maggioni AP AD - ANMCO Research Centre, Florence, Italy. AD - EURObservational Research Programme, European Society of Cardiology, Sophia Antipolis, France. FAU - Drozdz, Jaroslaw AU - Drozdz J AD - Department of Cardiology, Cardiology and Cardiac Surgery, Medical University of Lodz, Lodz, Poland. FAU - Filipiak, Krzysztof J AU - Filipiak KJ AD - Department of Cardiology, Public Central Teaching Hospital in Warsaw, Medical University of Warsaw, 1a Banacha St., 02-097, Warsaw, Poland. FAU - Opolski, Grzegorz AU - Opolski G AD - Department of Cardiology, Public Central Teaching Hospital in Warsaw, Medical University of Warsaw, 1a Banacha St., 02-097, Warsaw, Poland. LA - eng PT - Comparative Study PT - Journal Article PL - United States TA - Cardiovasc Drugs Ther JT - Cardiovascular drugs and therapy JID - 8712220 RN - 0 (Sodium Potassium Chloride Symporter Inhibitors) RN - 7LXU5N7ZO5 (Furosemide) RN - W31X2H97FB (Torsemide) SB - IM MH - Aged MH - Disease Progression MH - Female MH - Furosemide/adverse effects/*therapeutic use MH - Heart Failure/diagnosis/*drug therapy/mortality/physiopathology MH - Humans MH - Male MH - Middle Aged MH - Poland/epidemiology MH - Recovery of Function MH - Registries MH - Risk Factors MH - Sodium Potassium Chloride Symporter Inhibitors/adverse effects/*therapeutic use MH - Time Factors MH - Torsemide/adverse effects/*therapeutic use MH - Treatment Outcome OTO - NOTNLM OT - Furosemide OT - Heart failure OT - Loop diuretic OT - Torasemide EDAT- 2019/01/17 06:00 MHDA- 2019/07/23 06:00 CRDT- 2019/01/17 06:00 PHST- 2019/01/17 06:00 [pubmed] PHST- 2019/07/23 06:00 [medline] PHST- 2019/01/17 06:00 [entrez] AID - 10.1007/s10557-018-6843-5 [pii] AID - 10.1007/s10557-018-6843-5 [doi] PST - ppublish SO - Cardiovasc Drugs Ther. 2019 Feb;33(1):77-86. doi: 10.1007/s10557-018-6843-5.